{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:09:43Z","timestamp":1781683783908,"version":"3.54.5"},"reference-count":12,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,14]]},"DOI":"10.1182\/bloodadvances.2023011063","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T16:35:14Z","timestamp":1693413314000},"page":"6767-6770","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8058-3423","authenticated-orcid":false,"given":"Nathanael R.","family":"Fillmore","sequence":"first","affiliation":[{"name":"1VA Boston Healthcare System, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"La","sequence":"additional","affiliation":[{"name":"1VA Boston Healthcare System, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-1827","authenticated-orcid":false,"given":"Julie Tsu-Yu","family":"Wu","sequence":"additional","affiliation":[{"name":"4VA Palo Alto Healthcare System, Palo Alto, CA"},{"name":"5Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June K.","family":"Corrigan","sequence":"additional","affiliation":[{"name":"1VA Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-5124","authenticated-orcid":false,"given":"Westyn","family":"Branch-Elliman","sequence":"additional","affiliation":[{"name":"1VA Boston Healthcare System, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Monach","sequence":"additional","affiliation":[{"name":"1VA Boston Healthcare System, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary T.","family":"Brophy","sequence":"additional","affiliation":[{"name":"1VA Boston Healthcare System, Boston, MA"},{"name":"6Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6868-7011","authenticated-orcid":false,"given":"Nhan V.","family":"Do","sequence":"additional","affiliation":[{"name":"1VA Boston Healthcare System, Boston, MA"},{"name":"6Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"1VA Boston Healthcare System, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"issue":"12","key":"2023111415203430500_bib1","doi-asserted-by":"crossref","first-page":"e934","DOI":"10.1016\/S2352-3026(21)00278-7","article-title":"COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network","volume":"8","author":"Ludwig","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"2023111415203430500_bib2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood.2022016317","article-title":"Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders","volume":"140","author":"La","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2023111415203430500_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamaoncol.2021.5771","article-title":"Association of COVID-19 vaccination with SARS-CoV-2 infection in patients with cancer: a US Nationwide Veterans Affairs study","volume":"8","author":"Wu","year":"2022","journal-title":"JAMA Oncol"},{"issue":"24","key":"2023111415203430500_bib4","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.2019000406","article-title":"With equal access, African American patients have superior survival compared to White patients with multiple myeloma: a VA study","volume":"133","author":"Fillmore","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2023111415203430500_bib5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood.2021013714","article-title":"Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in multiple myeloma patients","volume":"139","author":"Henriquez","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2023111415203430500_bib6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-021-00530-3","article-title":"The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"issue":"26","key":"2023111415203430500_bib7","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1200\/JCO.21.02257","article-title":"Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma","volume":"40","author":"Nooka","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023111415203430500_bib8","doi-asserted-by":"crossref","first-page":"e202201479","DOI":"10.26508\/lsa.202201479","article-title":"Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: a cross sectional study","volume":"5","author":"Abella","year":"2022","journal-title":"Life Sci Alliance"},{"issue":"1","key":"2023111415203430500_bib9","doi-asserted-by":"crossref","first-page":"e2023011","DOI":"10.4084\/MJHID.2023.011","article-title":"Humoral immune response after anti-SARS-CoV-2 vaccine \u201cBooster\u201d dose in patients with monoclonal gammopathy of undetermined significance (MGUS)","volume":"15","author":"Sgherza","year":"2023","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"5","key":"2023111415203430500_bib10","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/bjh.18714","article-title":"Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients\u00a0with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial","volume":"201","author":"Faustini","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"2023111415203430500_bib11","doi-asserted-by":"crossref","first-page":"e1803","DOI":"10.1002\/cnr2.1803","article-title":"Loss of anti-spike antibodies following mRNA vaccination for COVID-19 among patients with multiple myeloma","volume":"6","author":"Stampfer","year":"2023","journal-title":"Cancer Rep"},{"issue":"6","key":"2023111415203430500_bib12","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","article-title":"Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)","volume":"37","author":"Terpos","year":"2023","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6767\/2089245\/blooda_adv-2023-011063-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6767\/2089245\/blooda_adv-2023-011063-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:21:19Z","timestamp":1699957279000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/21\/6767\/497697\/Even-after-SARS-CoV-2-booster-there-is-increased"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":12,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,11,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011063","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]}}}